The quarterly results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early November.
The quarterly results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early November.
Stay Ahead with STJ: Weekly Wisdom
In the fast-paced world of high-growth investing, staying informed is not just an advantage – it’s a necessity. That’s where our STJ: Weekly Wisdom newsletters come in. Each week, we bring you the latest insights, trends, and opportunities from the frontlines of the investment world. By subscribing to our newsletter, you ensure that you’re always in the know about the most promising sectors, innovative companies, and strategic investment approaches.
Don’t miss out on the knowledge that could define your next big success. Join our community of informed investors and let STJ: Weekly Wisdom be your guide in the ever-evolving landscape of high-growth investing.
Gain insights, receive dynamic opportunities directly to your inbox. Sign up now…